Imatinib
Gleevec, Glivec (imatinib) is a small molecule pharmaceutical. Imatinib was first approved as Gleevec on 2001-05-10. It is used to treat dermatofibrosarcoma, hypereosinophilic syndrome, lymphoid leukemia, myelodysplastic-myeloproliferative diseases, and myeloid leukemia amongst others in the USA. It has been approved in Europe to treat bcr-abl positive chronic myelogenous leukemia, dermatofibrosarcoma, gastrointestinal stromal tumors, hypereosinophilic syndrome, and myelodysplastic-myeloproliferative diseases amongst others. It is known to target tyrosine-protein kinase ABL1. Gleevec's patent is valid until 2021-12-19 (FDA).
| Trade Name | Glivec |
|---|---|
| Common Name | Imatinib |
| Indication | bcr-abl positive chronic myelogenous leukemia, dermatofibrosarcoma, gastrointestinal stromal tumors, hypereosinophilic syndrome, lymphoid leukemia, myelodysplastic-myeloproliferative diseases, myeloid leukemia, precursor cell lymphoblastic leukemia-lymphoma, systemic mastocytosis |
| Drug Class | Tyrosine kinase inhibitors |
